Compare ASTRAZENECA PHARMA with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ORCHID PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ORCHID PHARMA ASTRAZENECA PHARMA/
ORCHID PHARMA
 
P/E (TTM) x 114.4 -92.2 - View Chart
P/BV x 35.0 26.4 132.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   ORCHID PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ORCHID PHARMA
Sep-13
ASTRAZENECA PHARMA/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278194 658.8%   
Low Rs88335 2,521.7%   
Sales per share (Unadj.) Rs228.4276.5 82.6%  
Earnings per share (Unadj.) Rs10.4-79.2 -13.1%  
Cash flow per share (Unadj.) Rs16.3-43.5 -37.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.853.9 183.1%  
Shares outstanding (eoy) m25.0070.45 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.70.4 1,142.0%   
Avg P/E ratio x104.2-1.4 -7,210.9%  
P/CF ratio (eoy) x66.4-2.6 -2,521.2%  
Price / Book Value ratio x10.92.1 515.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0088,067 334.8%   
No. of employees `0001.42.8 48.4%   
Total wages/salary Rs m1,5352,527 60.8%   
Avg. sales/employee Rs Th4,210.96,956.1 60.5%   
Avg. wages/employee Rs Th1,132.2902.5 125.5%   
Avg. net profit/employee Rs Th191.1-1,993.0 -9.6%   
INCOME DATA
Net Sales Rs m5,71019,477 29.3%  
Other income Rs m123407 30.1%   
Total revenues Rs m5,83319,884 29.3%   
Gross profit Rs m4631,103 42.0%  
Depreciation Rs m1472,519 5.9%   
Interest Rs m05,227 0.0%   
Profit before tax Rs m438-6,236 -7.0%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m179-125 -142.9%   
Profit after tax Rs m259-5,580 -4.6%  
Gross profit margin %8.15.7 143.2%  
Effective tax rate %40.82.0 2,034.5%   
Net profit margin %4.5-28.7 -15.8%  
BALANCE SHEET DATA
Current assets Rs m3,20911,014 29.1%   
Current liabilities Rs m2,07032,060 6.5%   
Net working cap to sales %20.0-108.1 -18.5%  
Current ratio x1.60.3 451.4%  
Inventory Days Days7295 76.2%  
Debtors Days Days3534 104.1%  
Net fixed assets Rs m79029,440 2.7%   
Share capital Rs m50705 7.1%   
"Free" reserves Rs m2,4192,043 118.4%   
Net worth Rs m2,4693,800 65.0%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m4,60546,510 9.9%  
Interest coverage xNM-0.2-  
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.20.4 296.1%   
Return on assets %5.6-0.8 -740.2%  
Return on equity %10.5-146.9 -7.1%  
Return on capital %17.7-3.7 -475.0%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m3007,513 4.0%   
Fx outflow Rs m2,0155,649 35.7%   
Net fx Rs m-1,7151,865 -92.0%   
CASH FLOW
From Operations Rs m881,682 5.2%  
From Investments Rs m-94-9,860 0.9%  
From Financial Activity Rs mNA6,644 0.0%  
Net Cashflow Rs m-6-1,535 0.4%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.6 6.5%  
FIIs % 15.7 3.3 475.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 9.1 55.3 16.5%  
Shareholders   12,856 84,811 15.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS